IRVINE, Calif., Aug. 2, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company, today announced that one of the world's foremost contract manufacturers to the biopharma industry ("the Client") will convert its fleet of liquid nitrogen dewars supporting shipping of its contract manufacturing biologics and cell therapy businesses to Cryoport's industry-leading and comprehensive logistics solutions. Cryoport solutions include comprehensive order entry information, customs management, innovative real time tracking, intervention where necessary, advanced information technology, and archiving scientific and regulatory information.
By adopting this program, the Client will have access to Cryoport's Cryoport Express ® Shippers, advanced SmartPak II™ Condition Monitoring Systems and industry leading logistics management to ship temperature-controlled materials to and from its manufacturing facilities in the United States, the European Union and Asia. The SmartPak II™ Condition Monitoring System works seamlessly with Cryoport's Cryoportal™ logistics management platform to provide real-time conditions and location visibility. Cryoport's unique solutions provide automated alerts regarding temperature deviations, transit time deviations, LN2 hold time remaining, battery power levels and shipper orientation.
The Client is an established supplier to the pharmaceutical industry with global manufacturing and development expertise, advanced technologies and high-quality products. It has multiple manufacturing and R&D centers worldwide. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and services for the bioscience sector.
As the world's leading cryogenic logistics company, Cryoport supports many ground breaking and industry leading companies and organizations including Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center, ImmunoCellular Therapeutics, Kite Pharma, WuXi AppTec, Capricor, StemCell Technologies, Yancey Farms, Zoetis, Smithsonian Institution, Rockefeller University, University of Pennsylvania, etc.
Jerrell Shelton, CEO of Cryoport, Inc., stated, "It is indeed an honor to continue to have such well-respected multinational companies select Cryoport as their logistics partner. We have an offering that suits the needs of large and small companies in the life sciences industry and this latest customer win is a great example of how our solutions provide the best options for companies needing support in the vital area of temperature controlled logistics for the life sciences. Our Cryoport Express ® Shippers, in combination with our Cryoportal™ management platform, the SmartPak II™ Condition Monitoring System, and our most excellent Client Care Team provide our new Client with comprehensive solutions specifically developed to limit product degradation during transit -- anywhere in the world"
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Cryoport actively supports points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2016. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cryoport-to-support-world-leading-life-science-companys-custom-development-and-biologics-manufacturing-business-300307350.html
SOURCE Cryoport, Inc.